The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy

European Urology

Volumn 67, Issue 6, 2015, Pages 1009-1016

  Zumsteg, Zachary S ^a   Spratt, Daniel E ^a   Romesser, Paul B ^a   Pei, Xin ^a   Zhang, Zhigang ^a   Polkinghorn, William ^a   McBride, Sean ^a   Kollmeier, Marisa ^a   Yamada, Yoshiya ^a   Zelefsky, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biochemical failure; External beam radiotherapy; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; COHORT ANALYSIS; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORALITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER SPECIFIC MORTALITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; BLOOD; CANCER GRADING; CONFORMAL RADIOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TUMOR RECURRENCE;

AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929036165     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.09.028     Document Type: Article

References (29)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. R. Siegel, C. DeSantis, and K. Virgo Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 2012 220 241
3. S.P. Elliott, O.O. Adejoro, B.R. Konety, S.L. Jarosek, K.E. Dusenbery, and B.A. Virnig Intensity modulated radiation therapy replaces 3-dimensional conformal radiotherapy as prostate cancer treatment J Urol 187 2012 1253 1258
4. E. Rosenbaum, A. Partin, and M.A. Eisenberger Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations J Natl Compr Canc Netw 2 2004 249 256
5. D.E. Spratt, X. Pei, J. Yamada, M.A. Kollmeier, B. Cox, and M.J. Zelefsky Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer Int J Radiat Oncol Biol Phys 85 2013 686 692
6. W.R. Lee, G.E. Hanks, and A. Hanlon Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations J Clin Oncol 15 1997 230 238
7. S. Punnen, M.R. Cooperberg, and A.V. D'Amico Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature Eur Urol 64 2013 905 915
8. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
9. S.J. Freedland, E.B. Humphreys, and L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439
10. S.A. Boorjian, R.H. Thompson, and M.K. Tollefson Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893 899
11. J. Mohler, R.R. Bahnson, and B. Boston NCCN clinical practice guidelines in oncology: prostate cancer J Natl Compr Canc Netw 8 2010 162 200
12. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
13. D.G. Altman, B. Lausen, W. Sauerbrei, and M. Schumacher Dangers of using "optimal" cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 1994 829 835
14. R. Miller, and D. Siegmund Maximally selected chi square statistics Biometrics 38 1982 1011 1016
15. E.H. Kennedy, J.M. Taylor, D.E. Schaubel, and S. Williams The effect of salvage therapy on survival in a longitudinal study with treatment by indication Stat Med 29 2010 2569 2580
16. M.E. Nielsen, D.V. Makarov, E. Humphreys, L. Mangold, A.W. Partin, and P.C. Walsh Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion - "nadir + 2"? Urology 72 2008 389 393 discussion 94-5
17. D. Pfister, M. Bolla, and A. Briganti Early salvage radiotherapy following radical prostatectomy Eur Urol 65 2014 1034 1043
18. A. Goenka, J.M. Magsanoc, and X. Pei Long-term outcomes after high-dose postprostatectomy salvage radiation treatment Int J Radiat Oncol Biol Phys 84 2012 112 118
19. A.J. Stephenson, P.T. Scardino, and M.W. Kattan Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035 2041
20. B.J. Trock, M. Han, and S.J. Freedland Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760 2769
21. A.J. Stephenson, and J.A. Eastham Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy J Clin Oncol 23 2005 8198 8203
22. Y. Yamada, M.A. Kollmeier, and X. Pei A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy Brachytherapy 13 2014 111 116
23. R.J. Burri, N.N. Stone, P. Unger, and R.G. Stock Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 77 2010 1338 1344
24. P. Zhou, M.H. Chen, D. McLeod, P.R. Carroll, J.W. Moul, and A.V. D'Amico Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Clin Oncol 23 2005 6992 6998
25. J.W. Denham, A. Steigler, and C. Wilcox Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial Lancet Oncol 9 2008 1058 1068
26. A.V. D'Amico, J.W. Moul, P.R. Carroll, L. Sun, D. Lubeck, and M.H. Chen Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383
27. E.S. Antonarakis, Z. Feng, and B.J. Trock The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up BJU Int 2012 32 39
28. O.T. Okotie, W.J. Aronson, and J.A. Wieder Predictors of metastatic disease in men with biochemical failure following radical prostatectomy J Urol 171 2004 2260 2264
29. M.K. Buyyounouski, T. Pickles, L.L. Kestin, R. Allison, and S.G. Williams Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer J Clin Oncol 30 2012 1857 1863